

# Condensed Interim Consolidated Financial Statements

(Unaudited, expressed in Canadian dollars)

As at and for the three and nine months ended September 30, 2024 and 2023

# **Condensed Interim Consolidated Statements of Financial Position**

(Unaudited, expressed in Canadian dollars)

	September 30,	December 31,
As at	2024	2023
Assets		
Current assets		
Cash	234,126	136,172
Harmonized sales taxes recoverable	33,973	39,026
Deposits and prepaid expenses	131,771	61,880
Total current assets	399,870	237,078
Total assets	399,870	237,078
Accounts payable and accrued liabilities (note 3)	2,621,519	2,604,614
Liabilities  Current liabilities		
Total liabilities	2,621,519	2,604,614
Shareholders' deficiency		
Share capital (notes 5 & 8)	27,818,896	24,371,626
Contributed surplus (note 7)	6,088,155	5,527,644
Warrants (notes 6 & 8)	1,866,657	1,783,382
Deficit	(38,525,640)	(34,631,026)
Accumulated other comprehensive income	530,283	580,838
Total shareholders' deficiency	(2,221,649)	(2,367,536)
Total liabilities and shareholders' deficiency	399,870	237,078

Going concern (note 1) Subsequent events (notes 3, 6 & 7)

Approved for issuance by the Board on November 29, 2024

"Salim Hasham", Independent Director

"Steven Mannik", Independent Director

# Condensed Interim Consolidated Statements of Net Loss and Comprehensive Loss

(Unaudited, expressed in Canadian dollars except where otherwise noted)

	Three month		Nine month Septemb	· · · · · · · ·
	2024	2023	2024	2023
Operating expenses				
Administration	436,997	313,530	2,939,257	1,014,913
Legal and regulatory	88,211	124,512	174,687	153,818
Interest and bank charges	2,744	3,540	8,379	10,851
Investor relations and public reporting	63,665	51,208	174,113	117,916
Marketing and sales	12,501	995	38,116	137,271
Share-based compensation (notes 7& 8)	240,000	129,800	560,511	451,000
Total operating expenses	844,118	623,585	3,895,063	1,885,769
Other income				
Other income (expense)	-	(3)	449	(3)
Write-off of prepaid expenses	-		-	3,475
Total other income (expense)	-	(3)	449	3,472
Net loss	(844,118)	(623,588)	(3,894,614)	(1,882,297)
Items that may be reclassified subsequently to net loss:				
Foreign currency translation gain (loss)	25,136	(10,492)	(50,555)	88,817
Total comprehensive loss	(818,982)	(634,080)	(3,945,169)	(1,793,480)
Basic and & diluted loss per share (note 9)	(0.00)	(0.00)	(0.02)	(0.01)

# Condensed Interim Consolidated Statements of Changes in Shareholders' Deficiency

(Unaudited, expressed in Canadian dollars, except where otherwise noted)

	Share ca	Share capital				Accumulated		
-	Number of shares	Amount	Share subscription receivable	Warrants	Contributed surplus	other comprehensive income	Deficit	Total
Balance at December 31, 2023	150,755,407	24,371,626	-	1,783,382	5,527,644	580,838	(34,631,026)	(2,367,536)
Shares issued for cash (notes 5 & 8)	20,018,055	1,977,000	-	-	-	-	-	1,977,000
Shares issued for services (note 5)	10,900,000	1,635,000						1,635,000
Cost of issuance	-	(81,455)	-	-	-	-	-	(81,455)
Finder's warrants issued (notes 6 & 8)	-	(83,275)	-	83,275	-	-	-	-
Share-based compensation	-	-	-	-	560,511	-	-	560,511
Loss and comprehensive loss	-	-	-	-	-	(50,555)	(3,894,614)	(3,945,169)
Balance at September 30, 2024	181,673,462	27,818,896	-	1,866,657	6,088,155	530,283	(38,525,640)	(2,221,649)
Balance at December 31, 2022	133,514,823	22,703,718	(100,000)	1,761,886	4,844,144	487,093	(32,587,553)	(2,890,712)
Shares issued for cash	13,756,916	1,319,409	100,000	-	-	-	-	1,419,409
Cost of issuance	-	(137,174)	-	-	-	-	-	(137,174)
Finder's warrants issued	-	(18,850)	-	18,850	-	-	-	-
Share-based compensation	-	-	-	-	451,000	-	-	451,000
Loss and comprehensive loss	-	-	-	-	-	88,817	(1,882,297)	(1,793,480)
Balance at September 30, 2023	147,271,739	23,867,103	-	1,780,736	5,295,144	575,910	(34,469,850)	(2,950,957)

# **Condensed Interim Consolidated Statements of Cash Flows**

(Unaudited, expressed in Canadian dollars)

	Nine months ended September 30		
	2024	2023	
Operating activities			
Net loss	(3,894,614)	(1,882,297)	
Non-cash items:			
Share-based compensation	560,511	451,000	
Write-off of prepaid expenses	-	(3,475)	
	(3,334,103)	(1,434,772)	
Net change in non-cash working capital related to operations			
Harmonized sales taxes recoverable	5,053	102,865	
Deposits and prepaid expenses	(69,891)	51,314	
Accounts payable and accrued liabilities	1,651,905	(295,116)	
Due to related parties	-	(135)	
Cash used for operating activities	(1,747,036)	(1,575,844)	
Financing activities			
Issuance of common shares (net of issuance costs)	1,895,545	1,182,235	
Collection of subscription receivable	-	100,000	
Cash provided from financing activities	1,895,545	1,282,235	
Effect of foreign currency translation	(50,555)	88,817	
Decrease in cash for the period	97,954	(204,792)	
Cash, beginning of the year	136,172	263,569	
Cash, end of the period	234,126	58,777	

For the three and nine months ended September 30, 2024 and 2023, there were nominal amounts of cash interest paid.

# As at and for the three and nine months ended September 30, 2024 and 2023

# Notes to the Condensed Interim Consolidated Financial Statements

(Unaudited, expressed in Canadian dollars, except where otherwise noted)

#### 1. General information and going concern

DelphX Capital Markets Inc. ("**DelphX**" or the "**Company**") was incorporated as Seaside Exploration Partners Corp. ("**Seaside**") on October 21, 2016, pursuant to the *Business Corporations Act* (British Columbia), and was a Capital Pool Company, pursuant to the policies of the TSX Venture Exchange ("**TSXV**"). On April 25, 2018, DelphX Corporation and Seaside completed a Qualifying Transaction ("**QT**"), as is defined pursuant to TSXV Policy 2.4, pursuant to a definitive share-exchange agreement dated December 12, 2017. The QT constituted a reverse take-over ("**RTO**") of Seaside.

The principal address of the Company is 15 Prince Arthur Street, Toronto, Ontario, M5R 1B2. DelphX's principal business activity is to develop a global facility for transparent offering, purchase, sale, collection and storage of certain fixed income securities and derivatives, and to manage data, research, analytics, and valuations of such instruments.

These unaudited interim condensed consolidated financial statements (the "Financial Statements") have been prepared using International Financial Reporting Standards ("IFRS") applicable to going concern, which contemplates the realization of assets and settlement of liabilities as they fall due in the normal course of business for the foreseeable future. The Company is in the development stage and has not yet realized profitable operations and has relied on non-operational sources of financing to fund operations. DelphX's ability to continue as a going concern is dependent on successfully executing its business plan, which includes the raising of additional funds. The Company will continue to seek additional forms of debt or equity financing, but it cannot provide assurance that it will be successful in doing so. These material uncertainties cast significant doubt as to the ability of the Company to continue as a going concern. The Financial Statements do not reflect the adjustments to the carrying amounts of assets and liabilities and the reported expenses and consolidated statement of financial position classifications that would be necessary if the Company were unable to realize its assets and settle its liabilities as a going concern in the normal course of operations. Such adjustments could be material.

#### 2. Basis of preparation

#### Statement of compliance

The Financial Statements have been prepared in accordance with IAS 34 Interim Financial Reporting and do not include all of the information required for full annual financial statements. The Financial Statements should be read conjunction with the Company's most recent annual financial statements for the years ended December 31, 2023 and 2022 ("Annual Financial Statements") which were prepared in conformity with IFRS as issued by the International Accounting Standards Board ("IASB") and interpretations issued by the International Financial Reporting Interpretations Committee.

# As at and for the three and nine months ended September 30, 2024 and 2023

## **Notes to the Condensed Interim Consolidated Financial Statements**

(Unaudited, expressed in Canadian dollars, except where otherwise noted)

#### Basis of presentation and measurement

The Financial Statements have been prepared on an accrual basis and are based on historical cost basis, except for certain financial instruments that are measured on amortized cost or fair value.

These Financial Statements follow the same accounting policies and methods of application, basis of measurement, critical accounting judgements and significant estimates used to prepare the Annual Financial Statements.

Prior period amounts have been reclassified as required to conform with the current period presentation.

The Financial Statements were approved and authorized for issuance by the Board on November 29, 2024.

# Basis of consolidation and foreign currency translation

The Financial Statements include the accounts of the Company and its directly and indirectly wholly owned subsidiaries. All inter-company transactions, balances, income, and expenses between the consolidated entities are eliminated on consolidation.

The Company's presentation currency is the Canadian dollar which is also its functional currency. The functional currencies of the Company's subsidiaries were determined based on the principal currency of the economic environment in which each entity operates. The application of foreign currency translation adjustments are detailed in the Annual Financial Statements.

Details on the Company's subsidiaries are as follows:

Subsidiary	Jurisdiction	Incorporation date	Functional currency	Status
DelphX Corporation	Delaware, USA	February 18, 2016	United States dollar	Active
DelphX Services Corporation	<b>United States</b>	August 4, 2011	United States dollar	Active
DelphX Data Corporation	Canada	February 21, 2018	Canadian dollar	Active
Quantem Capital LLC	Delaware, USA	September 3, 2021	United States dollar	Active
Quantem Capital Corporation	Bermuda	April 11, 2018	United States dollar	Inactive

## 3. Accounts payable and accrued liabilities

	September 30,	December 31,
	2024	2023
Administration	608,565	679,197
Investor relations and public reporting	10,586	13,027
Legal and regulatory	1,939,088	1,845,803
Research and development	63,280	66,587
·	2,621,519	2,604,614

# As at and for the three and nine months ended September 30, 2024 and 2023

#### **Notes to the Condensed Interim Consolidated Financial Statements**

(Unaudited, expressed in Canadian dollars, except where otherwise noted)

## 4. Capital management

The Company's main objective in managing capital is to ensure sufficient liquidity to pursue and fund product development, production, and promotion. Secondarily, the Company strives to continue to fund its growth strategy, while at the same time taking a conservative approach toward financial leverage and management of financial risk. The Company's capital is considered to be its shareholders' equity (deficiency). The Company's primary uses of capital are used for operations to support the launch of the Company's Credit Rating Security ("CRS") product. The Company currently funds these requirements from existing cash resources and/or cash raised through the issuance of equity. The Company's objectives when managing capital is to ensure the Company will continue to have enough liquidity so that it can provide its products and services to customers and returns to its shareholders. The Company monitors its capital on the basis of the adequacy of its cash resources to fund its business plan.

Management reviews its capital management approach on an ongoing basis and believes that this approach, given the relative size of the Company, is reasonable.

There were no changes in the Company's approach to capital management during the nine months ended September 30, 2024. The Company is not subject to any significant capital requirements by lending institutions or regulatory bodies, other than by the continued listing requirements of the TSXV.

#### 5. Share capital

#### Authorized

DelphX's authorized share capital consists of an unlimited number of common shares at no par value.

#### Issued and outstanding

As at September 30, 2024, the Company had 181,673,462 common shares outstanding (December 31, 2023 – 150,755,407).

On January 30, 2024, the Company successfully closed the issuance of 3,904,166 Units at a subscription price of \$0.12 per unit for gross proceeds of \$468,500 (the "January 2024 Offering"). Each unit consists of one common share and one common share purchase warrant. Each warrant entitles the holder to purchase one common share at a price of \$0.20, for a period of two years from the date of issuance. The securities issued will be subject to a hold period of four months plus one day from the date of issuance. In connection with the January 2024 Offering, the Company paid a cash finder's fee of \$8,400 and issued 70,000 finder's warrants. The finder's warrants will be exercisable at \$0.20 each for a period of two years after issuance.

On April 23, 2024, the Company successfully closed the issuance of 5,000,000 Units at a subscription price of \$0.08 per unit for gross proceeds of \$400,000 (the "April 2024 Offering"). Each unit consists of one common share and one common share purchase warrant. Each warrant entitles the holder to purchase one common share at a price of \$0.20, for a period of five years from the date of issuance. The securities issued will be subject to a hold period of four months plus one day from the date of issuance. In connection with the April 2024 Offering, the Company paid a cash finder's fee of \$11,200 and issued 140,000 finder's warrants. The finder's Warrants will be exercisable at \$0.20 each for a period of five years after issuance.

# As at and for the three and nine months ended September 30, 2024 and 2023

## **Notes to the Condensed Interim Consolidated Financial Statements**

(Unaudited, expressed in Canadian dollars, except where otherwise noted)

On June 20, 2024, the Company successfully closed the issuance of 2,650,000 Units at a subscription price of \$0.08 per unit for gross proceeds of \$212,000 (the "June 2024 Offering"). Each unit consists of one common share and one common share purchase warrant. Each warrant entitles the holder to purchase one common share at a price of \$0.20, for a period of five years from the date of issuance. The securities issued will be subject to a hold period of four months plus one day from the date of issuance. In connection with the June 2024 Offering, the Company paid a cash finder's fee of \$3,640 and issued 52,000 finder's warrants. The finder's warrants will be exercisable at \$0.20 each for a period of five years after issuance.

On July 3, 2024, the Company issued 10,900,000 common shares as settlement of \$1.6 million in accounts payable outstanding from the first guarter of 2024.

On July 30, 2024, the Company successfully closed the issuance of 3,972,223 Units at a subscription price of \$0.09 per unit for gross proceeds of \$357,500 (the "July 2024 Offering"). Each unit consists of one common share and one common share purchase warrant. Each warrant entitles the holder to purchase one common share at a price of \$0.25, for a period of five years from the date of issuance. The securities issued will be subject to a hold period of four months plus one day from the date of issuance. In connection with the July 2024 Offering, the Company paid a cash finder's fee of \$3,500 and issued 38,889 finder's warrants. The finder's warrants will be exercisable at \$0.25 each for a period of five years after issuance.

On August 23, 2024, the Company successfully closed the issuance of 4,491,666 Units at a subscription price of \$0.12 per unit for gross proceeds of \$539,000 (the "**August 2024 Offering**"). Each unit consists of one common share and one common share purchase warrant. Each warrant entitles the holder to purchase one common share at a price of \$0.25, for a period of five years from the date of issuance. The securities issued will be subject to a hold period of four months plus one day from the date of issuance. In connection with the August 2024 Offering, the Company paid a cash finder's fee of \$37,730 and issued 314,417 finder's warrants. The finder's warrants will be exercisable at \$0.25 each for a period of five years after issuance.

After the reporting date, the Company announced the following:

On November 15, 2024, the Company announced its intention to issue 2,900,834 Units at a subscription price of \$0.12 per unit for gross proceeds of \$348,100 (the "**November 2024 Offering**"). Each unit will consist of one common share and one common share purchase warrant. Each warrant will entitle the holder to purchase one common share at a price of \$0.20, for a period of five years from the date of issuance. The securities issued will be subject to a hold period of four months plus one day from the date of issuance. In connection with the November 2024 Offering, the Company will pay a cash finder's fee and issue finders' warrants to eligible finders. The finder's warrants will be exercisable at \$0.20 each for a period of five years after issuance.

On November 20, 2024 and November 27, 2024, the Company announced that it will issue 138,888 common shares and 428,571 common shares, respectively, in satisfaction of consulting fees payable.

# As at and for the three and nine months ended September 30, 2024 and 2023

## **Notes to the Condensed Interim Consolidated Financial Statements**

(Unaudited, expressed in Canadian dollars, except where otherwise noted)

#### 6. Warrants

During the nine months ended September 30, 2024 the Company issued 20,018,055 warrants in connection with the unit financings disclosed in note 5. The warrants portion of the units issued were valued at nil using the residual value method.

During the nine months ended September 30, 2024, the company issued 608,806 finder's warrants in connection with the unit financings disclosed in note 5. The fair value of the finder's warrants, being \$83,275, were estimated using the Black-Scholes option pricing model with the following assumptions:

Issuance	Number of finder's warrants issued	Exercise price	Risk-free rate	Expected life	Estimated Volatility	Dividend Yield
January 30, 2024	70,000	\$0.20	4.04%	2 years	127%	0%
April 23, 2024	140,000	\$0.20	3.79%	5 years	171%	0%
June 20, 2024	45,500	\$0.20	3.36%	5 years	168%	0%
July 30, 2024	38,889	\$0.25	3.16%	5 years	167%	0%
August 23, 2024	314,417	\$0.25	2.93%	5 years	168%	0%

During the nine months ended September 30, 2024, the following warrants expired:

Number of Warrants	Туре	Exercise Price	Expiry Date
8,116,500	Warrants	\$0.30	May 15, 2024
4,133,334	Warrants	\$0.24	May 31, 2024
130,200	Finder's Warrants	\$0.35	May 10, 2024
50,050	Finder's Warrants	\$0.30	August 25, 2024
12.430.084			

The outstanding issued warrants balance as at September 30, 2024, is comprised of the following items:

Number of Warrants	Туре	Exercise Price	Expiry Date
5,501,666	Warrants	\$0.20	February 27, 2025
150,000	Finder's Warrants	\$0.20	February 27, 2025
2,833,334	Warrants	\$0.08	March 26, 2025
116,667	Finder's Warrants	\$0.06	March 26, 2025
160,000	Warrants	\$0.08	April 23, 2025
916,667	Warrants	\$0.08	April 24, 2025
4,718,332	Warrants	\$0.10	June 12, 2025
143,500	Finder's Warrants	\$0.08	June 12, 2025
5,430,250	Warrants	\$0.15	June 29, 2025
200,000	Finder's Warrants	\$0.15	June 29, 2025
4,825,715	Warrants	\$0.30	August 25, 2025 <sup>(1)</sup>
2,825,000	Warrants	\$0.15	August 30, 2025

# As at and for the three and nine months ended September 30, 2024 and 2023

## **Notes to the Condensed Interim Consolidated Financial Statements**

(Unaudited, expressed in Canadian dollars, except where otherwise noted)

Number of Warrants	Туре	Exercise Price	Expiry Date
3,483,668	Warrants	\$0.20	November 2, 2025
31,500	Finder's Warrants	\$0.20	November 2, 2025
5,422,221	Warrants	\$0.15	December 7, 2025 <sup>(2)</sup>
3,904,166	Warrants	\$0.20	January 30, 2026
70,000	Finder's Warrants	\$0.20	January 30, 2026
5,680,000	Warrants	\$0.15	April 15, 2026
280,000	Finder's Warrants	\$0.10	April 15, 2026
458,245	Finder's Warrants	\$0.33	July 14, 2026
4,982,727	Warrants	\$0.35	May 27, 2027
5,000,000	Warrants	\$0.20	April 23, 2029
140,000	Finder's Warrants	\$0.20	April 23, 2029
2,650,000	Warrants	\$0.20	June 20, 2029
45,500	Finder's Warrants	\$0.20	June 20, 2029
3,972,223	Warrants	\$0.25	July 30, 2029
38,889	Finder's Warrants	\$0.25	July 30, 2029
4,491,666	Warrants	\$0.25	August 23, 2029
314,417	Finder's Warrants	\$0.25	August 23, 2029
68,786,353			

<sup>(1)</sup> In August 2024, the Company was granted permission by the Exchange to extend the expiry date of these warrants from August 25, 2024 to August 25, 2025.

#### 7. Contributed surplus

## **Options**

In accordance with the Plan, Options may be granted to certain officers, directors, employees, and consultants of the Company with a maximum term of 10 years and variable vesting as determined by the directors of the Company upon issuance. The Plan allows for the issuance of Options up to 10% of the issued and outstanding common shares. As at September 30, 2024, the Company had 1,354,346 (December 31, 2023 – 2,075,541) Options available for issuance. A continuity of the unexercised Options to purchase common shares is as follows:

	Weighted average exercise price	Number of options
Outstanding at December 31, 2023	\$0.23	13,000,000
Issued	\$0.24	8,313,000
Expired and forfeited	\$0.29	(4,500,000)
Outstanding at September 30, 2024	\$0.21	16,813,000
Exercisable at September 30, 2024	\$0.21	16,813,000

<sup>(2)</sup> In November 2024, the Company was granted permission by the Exchange to extend the expiry date of these warrants from November 29, 2024 to December 7, 2025.

# As at and for the three and nine months ended September 30, 2024 and 2023

## **Notes to the Condensed Interim Consolidated Financial Statements**

(Unaudited, expressed in Canadian dollars, except where otherwise noted)

On January 8, 2024 and January 12, 2024, the Board of Directors approved the granting of 750,000 Options and 150,000 Options, respectively, to consultants and advisors under the Plan. The Options have a two-year maturity and are exercisable for common shares of the Company at an exercise price of \$0.25 per common share.

On February 27, 2024, 1,000,000 Options granted on April 26, 2023 with an exercise price of \$0.15 to a consultant expired following the termination of the agreement on November 29, 2023 which resulted in the acceleration of the Option expiry to 90 days following termination.

On March 17, 2024, the Board of Directors approved the granting of 645,000 Options to a consultant under the Plan. The Options have a two-year maturity and are exercisable for common shares of the Company at an exercise price of \$0.15 per common share.

On April 7, 2024, 1,200,000 Options with an exercise price of \$0.50 expired and on May 7, 2024, 300,000 Options with an exercise price of \$0.20 expired.

On May 13, 2024, the Board of Directors approved the granting of 3,918,000 Options to consultants and advisors under the Plan. The Options have a two-year maturity and are exercisable for common shares of the Company at an exercise price of \$0.25 per common share.

On July 29, 2024, 500,000 Options granted on January 8, 2024 with an exercise price of \$0.25 to a consultant expired following the termination of the agreement In April 2024 which resulted in the acceleration of the Option expiry to 90 days following termination.

On August 26, 2024, the Board of Directors approved the granting of 1,200,000 Options to consultants and advisors under the Plan. The Options have a two-year maturity and are exercisable for common shares of the Company at an exercise price of \$0.25 per common share.

On September 9, 2024, 1,500,000 Options with an exercise price of \$0.25 expired.

On September 20, 2024, the Board of Directors approved the granting of 1,650,000 Options to consultants and advisors under the Plan. The Options have a two-year maturity and are exercisable for common shares of the Company at an exercise price of \$0.25 per common share.

The grant-date fair value for the 8,313,000 Options granted during the nine months ended September 30, 2024 was estimated using the Black-Scholes option pricing model with the following assumptions:

	Number of options	Exercise	Risk-	Expected	Estimated	Dividend	Vested
Date Issued	issued	price	free rate	life	Volatility	Yield	Fair value
January 8, 2024	750,000	\$0.25	4.03%	2 years	126%	0%	61,500
January 12, 2024	150,000	\$0.25	4.03%	2 years	126%	0%	12,300
March 17, 2024	645,000	\$0.15	4.27%	2 years	128%	0%	62,565
May 13, 2024	3,918,000	\$0.25	4.29%	2 years	127%	0%	184,146
August 26, 2024	1,200,000	\$0.25	3.25%	2 years	132%	0%	121,200
September 20,2024	1,650,000	\$0.25	2.92%	2 years	135%	0%	118,800
	8,313,000						560,511

# As at and for the three and nine months ended September 30, 2024 and 2023

## **Notes to the Condensed Interim Consolidated Financial Statements**

(Unaudited, expressed in Canadian dollars, except where otherwise noted)

The table below provides additional information regarding the outstanding Options as at September 30, 2024:

Number outstanding	Number exercisable	Exercise price	Expiry date	Vested Fair Value
950,000	950,000	\$0.15	December 23, 2024	50,350
650,000	650,000	\$0.15	January 18, 2025	60,450
750,000	750,000	\$0.20	February 9, 2025	86,250
1,250,000	1,250,000	\$0.20	March 8, 2025	107,500
1,975,000	1,975,000	\$0.20	July 7, 2025	86,900
1,100,000	1,100,000	\$0.20	July 28, 2025	42,900
2,325,000	2,325,000	\$0.25	December 7, 2025	232,500
250,000	250,000	\$0.25	January 8, 2026	20,500
150,000	150,000	\$0.25	January 12, 2026	12,300
645,000	645,000	\$0.15	March 17, 2026	62,565
3,918,000	3,918,000	\$0.25	May 13, 2026	184,146
1,200,000	1,200,000	\$0.25	August 26, 2026	121,200
1,650,000	1,650,000	\$0.25	September 20, 2026	118,800
16,813,000	16,813,000			

#### **Share-based payments**

Vesting of Options accounted for share-based compensation for the three months and nine months ended September 30, 2024 of \$240,000 (2023- \$129,800) and \$560,511 (2023- \$451,000), respectively.

#### 8. Related party transactions and balances

#### Equity transactions

The private placements disclosed in note 5 during the nine months ended September 30, 2024 included the issuance of 1,854,166 units to related parties for gross proceeds of \$165,000 (December 31, 2023 – 3,455,250 units for gross proceeds of \$284,420) and were subject to the same terms and conditions as those offerings disclosed under note 5.

#### Key management compensation

Key management includes those individuals having authority and responsibility for planning, directing, and controlling the activities of the Company directly or indirectly. Key management includes the directors, the chief executive officer, the current and former chief financial officer and the chief actuary and risk officer. Compensation paid or accrued to key management is detailed below:

	Three months ended September		Nine months ended September	
	2024	2023	2024	2023
Administration	172,105	130,957	477,841	426,880
Share based compensation	205,400	33,100	232,425	101,900
Key management compensation	377,505	164,057	710,266	528,780

# As at and for the three and nine months ended September 30, 2024 and 2023

## **Notes to the Condensed Interim Consolidated Financial Statements**

(Unaudited, expressed in Canadian dollars, except where otherwise noted)

#### 9. Loss per share

The calculation of per share amounts is based on the following:

	Three months ende	ed September 30,	Nine months end	led September 30
	2024	2023	2024	2023
Net loss - basic	(844,118)	(623,588)	(3,894,614)	(1,882,297)
Effect of dilutive securities	-	-	-	-
Net loss - diluted	(844,118)	(623,588)	(3,894,614)	(1,882,297)
Weighted averages shares - basic	177,552,004	145,398,641	163,200,581	140,018,290
Effect of dilutive securities	-	-	-	<u>-</u>
Weighted average shares - diluted	177,552,004	145,398,641	163,200,581	140,018,290
Per share - basic	(0.00)	(0.00)	(0.02)	(0.01)
Per share - diluted	(0.00)	(0.00)	(0.02)	(0.01)

In computing per share amounts for the three and nine months ended September 30, 2024, 16,813,000 Options (September 30, 2023 –13,000,000) and 68,786,353 warrants (September 30, 2023 – 37,645,221) and were excluded as the Company had a net loss and their inclusion would be anti-dilutive.

#### 10. Financial instruments

Fair value represents the price at which a financial instrument could be exchanged in an orderly market, in an arm's length transaction between knowledgeable and willing parties who are under no compulsion to act. The Company classifies the fair value of the financial instruments according to the following hierarchy based on the amount of observable inputs used to value the financial instrument:

- Level 1 fair value measurements are those derived from quoted prices (adjusted) in the active market for identical assets or liabilities.
- Level 2 fair value measurements are those derived from inputs other than quoted prices that are observable for the assets or liability, either directly (i.e. as prices) or indirectly (derived from prices).
- Level 3 fair value measurements are those derived from valuation techniques that include inputs for the assets or liability that are not based on observable market data (unobservable inputs).

If the inputs used to measure the fair value of an asset or liability fall into different levels of the fair value hierarchy, then the fair value measurement is categorized in its entirety in the same level of the fair value hierarchy as the lowest level input that is significant to the entire measurement.

The carrying value of cash, harmonized sales taxes recoverable, deposits and prepaid expenses, and accounts payable and accrued liabilities approximates fair value due to the short-term nature of these financial instruments.

The Company recognizes transfers between levels of the fair value hierarchy at the end of the reporting period during which the change has occurred. There have been no transfers between levels during the year.

Page | 13